AnaptysBio, Inc. (ANAB)
NASDAQ: ANAB · Real-Time Price · USD
48.21
-2.05 (-4.08%)
Oct 1, 2026, 2:06 PM EDT - Market open

AnaptysBio Financials Overview

Millions USD. Fiscal year is Jul - Jun.

Revenue & Profits

Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Jun '26 Dec '25 Dec '24 Dec '23 Dec '22
Revenue
106.09106.09234.691.2817.1610.29
Revenue Growth
-13.86%-54.78%157.01%432.03%66.78%-83.72%
Gross Profit
111.42111.42238.2579.79-115.13-78.51
Operating Income
65.765.7226.966.15-157.07-115.15
Net Income
261.99261.99-13.23-145.23-163.62-128.72
Earnings Per Share
7.007.00-0.44-4.91-6.08-4.57
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Jun '26 Dec '25 Dec '24 Dec '23 Dec '22
Cash & Investments
164.14164.14211.64285.37390.9441.24
Total Debt
269.59269.59290.64369.46328.62323.86
Net Cash (Debt)
-105.45-105.45-79-84.0962.28117.38
Net Cash Growth
-----46.94%-57.48%
Net Cash Per Share
-2.81-2.81-2.61-2.852.314.17

Cash Flow & CapEx

Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Jun '26 Dec '25 Dec '24 Dec '23 Dec '22
Operating Cash Flow
-105.12-105.1219.7-135.34-120.8-73.59
Capital Expenditures
-----0.81-0.36
Free Cash Flow
-105.12-105.1219.7-135.34-121.61-73.95
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Jun '26 Dec '25 Dec '24 Dec '23 Dec '22
Gross Margin
105.03%105.03%101.55%87.41%--
Operating Margin
61.93%61.93%96.72%72.47%-915.50%-1119.41%
Pretax Margin
-9.60%-9.60%69.17%34.11%-953.68%-1251.09%
Profit Margin
246.96%246.96%-5.64%-159.11%-953.66%-1251.33%
FCF Margin
-99.09%-99.09%8.40%-148.27%-708.79%-718.88%

Valuation

Fiscal YearCurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingOct '26 Jun '26 Dec '25 Dec '24 Dec '23 Dec '22
PE Ratio
6.897.63----
Forward PE
13.5637.9014.6814.6814.6814.68
P/FCF Ratio
--68.15---
PS Ratio
13.6718.845.724.4133.1885.65